Skip to main content
. 2016 Mar 9;7(15):20704–20717. doi: 10.18632/oncotarget.8007

Figure 3. Association of EPB41L4A-AS2 expression with survival of breast cancer patients.

Figure 3

(A) EPB41L4A-AS2 expression and OS of breast cancer patients in cohort I (N = 250). (B) EPB41L4A-AS2 expression and OS in TP53 wild-type patients in cohort III (N = 187). (C) EPB41L4A-AS2 expression and RFS of breast cancer patients in cohort III (N = 3,554). (D) EPB41L4A-AS2 expression and DMFS of breast cancer patients in cohort III (N = 1,609).